

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09868123	
	Filing Date		2002-04-02	
	First Named Inventor	Mary Collins		
	Art Unit	1647		
	Examiner Name	Regina M. DeBerry		
	Attorney Docket Number	W2023-7013US		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		09868123
Filing Date		2002-04-02
First Named Inventor	Mary Collins	
Art Unit	1647	
Examiner Name	Regina M. DeBerry	
Attorney Docket Number	W2023-7013US	

/RMD/	1	Appeal Brief of Opposition to EP 1 141 286 B1, filed by UCB Pharma S.A. and received by the European Patent Office on July 10, 2007. considered do not print	<input type="checkbox"/>
	2	Appeal Brief of Opposition to EP 1 141 286 B1, filed by AstraZeneca AB and received by the European Patent Office on July 10, 2007. considered do not print	<input type="checkbox"/>
	3	Appeal Brief of Opposition to EP 1 141 286 B1, filed by Glaxo Group Limited and received by the European Patent Office on July 19, 2007. considered do not print	<input type="checkbox"/>
	4	Proprietor's Brief in the Opposition of EP 1 141 286 B1, received by the European Patent Office on July 7, 2008. considered do not print	<input type="checkbox"/>
	5	International Search Report in related International Application PCT/US99/29493, dated April 25, 2000. considered do not print	<input type="checkbox"/>
	6	International Search Report in related International Application PCT/US03/21454, dated May 21, 2008. considered do not print	<input type="checkbox"/>
	7	International Search Report in related International Application PCT/US07/025418, dated July 14, 2008. considered do not print	<input type="checkbox"/>
	8	BREE, "IL-13 blockade reduces lung inflammation after Ascaris suum challenge cynomolgus monkeys," J Allergy Clin Immunol, Article in Press, pp. 1-7 (2007).	<input type="checkbox"/>
	9	VUGMEYSTER et al., "Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms," International Immunopharmacology, 8:477-483 (2008).	<input type="checkbox"/>
	10	FICHTNER-FEIGL et al., "IL-13 signaling through the IL-13x2 receptor involved in induction of TGF-B1 production and fibrosis," Nature Medicine, 12(1):99-106 (2006).	<input type="checkbox"/>
/RMD/	11	KASAIAN et al., " Efficacy of IL-13 neutralization in a sheep model of experimental Asthma," American Journal of Respiratory Cell and Molecular Biology, 36:368-376 (2007).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		09868123
Filing Date		2002-04-02
First Named Inventor	Mary Collins	
Art Unit	1647	
Examiner Name	Regina M. DeBerry	
Attorney Docket Number	W2023-7013US	

/RMD/	12	ANDREWS et al., "Kinetic analysis of the interleukin-13 receptor complex," The Journal of Biological Chemistry, 277 (48):46073-46078 (2002).	<input type="checkbox"/>
	13	NASEER et al., "Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy," Am. J. Respir. Crit. Care Med., 155:845-851 (1997).	<input type="checkbox"/>
	14	PAWANKAR et al., "Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells," J. Clin. Invest., 99:1492-1499 (1997).	<input type="checkbox"/>
	15	POSTMA et al., "Genetic susceptibility to asthma-bronchial hyperresponsiveness coinherited with a major gene for atopy," N. Engl. J. Med., 333:894-900 (1995).	<input type="checkbox"/>
	16	PUNNONEN and DE VRIES, October 1998, In: Allergy and Allergic Diseases, J.A. Denburg ed., Human Press Inc., Totowa, New Jersey, pp. 13-40.	<input type="checkbox"/>
	17	TEKKANAT et al., "IL-13-Induced Airway Hyperreactivity During Respiratory Syncytial Virus Infection Is STAT6 Dependent," The Journal of Immunology, 166:3542-3548 (2001).	<input type="checkbox"/>
	18	TERABE et al., "NKT cells-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway," Nature Immunology, 1(6):515-520 (2000).	<input type="checkbox"/>
	19	TOMKINSON et al., "A Murine IL-4 Receptor Antagonist That Inhibits IL-4- and IL-13-Induced Responses Prevents Antigen-Induced Airway Eosinophilia and Airway Hyperresponsiveness," The Journal of Immunology, 166:5792-5800, (2001).	<input type="checkbox"/>
	20	URBAN et al., "IL-13-Mediated Worm Expulsion Is B7 Independent and IFN-gamma Sensitive," The Journal of Immunology, 164:4250-4256 (2000).	<input type="checkbox"/>
	21	VAN DER POuw KRAAN et al., "The role of IL-13 in IgE synthesis by allergic asthma patients," Clin. Exp. Immunol., 111:129-135 (1998).	<input type="checkbox"/>
/RMD/	22	VOGEL, "Interleukin-13's Key Role in Asthma Shown," Science, 282:2168 (1998).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		09868123
Filing Date		2002-04-02
First Named Inventor	Mary Collins	
Art Unit	1647	
Examiner Name	Regina M. DeBerry	
Attorney Docket Number	W2023-7013US	

/RMD/	23	WALTER et al., "Critical Role for IL-13 in the Development of Allergen-Induced Airway Hyperreactivity," The Journal of Immunology, 167:4668-4675 (2001).	<input type="checkbox"/>
	24	WARNER, "Bronchial hyperresponsiveness, atopy, airway inflammation, and asthma," Pediatr. Allergy Immunol., 9:56-60 (1998).	<input type="checkbox"/>
	25	WILLS-KARP et al., "Polymorphisms Not Found in the IL-13 Gene Promotor," Science, 284:1431 (1999).	<input type="checkbox"/>
	26	WILLS-KARP et al., "Interleukin-13: Central Mediator of Allergic Asthma", Science, 282(5397):2258-2261 (1998).	<input type="checkbox"/>
	27	YSSEL et al., "The role of IgE in asthma," Clin. Exp. Allergy, 28(Suppl. 5):104-109 (1998).	<input type="checkbox"/>
	28	ZURAWSKI et al., "Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction," EMBO J., 12:2663-2670 (1993).	<input type="checkbox"/>
	29	ZURAWSKI et al., "The Primary Binding Subunit of the Human Interleukin-4 Receptor Is Also a Component of the Interleukin-13 Receptor," The Journal of Biological Chemistry, 270(23):13869-13878 (1995).	<input type="checkbox"/>
	30	GRUNIG et al., "Requirement for IL-13 Independently of IL-4 in Experimental Asthma," Science, 282, 18 December 1998, pp. 2261-2263.	<input type="checkbox"/>
	31	Appeal Brief of Opposition to EP 1 141 286 B1, filed by Genentech, Inc. and received by the European Patent Office on July 9, 2007. considered do not print	<input type="checkbox"/>
/RMD/	32	Appeal Brief of Opposition to EP 1 141 286 B1, filed by George W. Schlich and received by the European Patent Office on July 9, 2007. considered do not print	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

Add

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09868123
Filing Date	2002-04-02
First Named Inventor	Mary Collins
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	W2023-7013US

EXAMINER SIGNATURE

Examiner Signature	/Regina DeBerry/ (10/29/2008)	Date Considered	
--------------------	-------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.